Journals / European Journal of Therapeutics / 2021 / Cilt: 27 - Sayı: 1

Whole Blood Viscosity as a Marker of Thrombosis in Cushing’s Disease: An Actor or Ineffective Factor

Pages
73–77
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further large-scale studies are necessary toconfirm our study findings.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: There is a tendency for thromboembolic events (TE) in Cushing’s disease (CD) because of the cortisol excess itself andassociated risk factors for TE.
📊
Key Findings & Data:Herein, we aimed to compare WBV between patients with CD and the control group and evaluate the impact of CD treatment on WBV.Methods: A total of 34 patients with CD without prior TE history and 30 subjects as the control group were enrolled between 2015and 2020.
💡
Conclusion & Impact:However, further large-scale studies are necessary toconfirm our study findings.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: There is a tendency for thromboembolic events (TE) in Cushing’s disease (CD) because of the cortisol excess itself andassociated risk factors for TE. Whole blood viscosity (WBV) as a measure of hemorheological features may impact the developmentof TE. However, limited data are available on the status of these changes in CD. Herein, we aimed to compare WBV between patients with CD and the control group and evaluate the impact of CD treatment on WBV.Methods: A total of 34 patients with CD without prior TE history and 30 subjects as the control group were enrolled between 2015and 2020. Demographic, clinical, and laboratory characteristics of the study groups were recorded. WBV was calculated using thede Simone formula.Results: Among the corticotroph pituitary adenomas of the CD group, 32 of 34 were microadenomas, and 2 were macroadenomas.Postoperative remission was achieved in all patients. However, a recurrence was observed in 10 patients at 5.8±3.2 year follow-up.There was no difference between baseline WBV, at both low and high shear rates, between the CD and control groups (p>0.05).Furthermore, the WBVs at both low and high shear rates were also similar before and after treatment in the CD group (16.3±1.8versus 15.4±1.7, p=0.2, for WBV at the high shear rate; 40.5±38.2 versus 25.4±35.2, p=0.23, at the low shear rate).Conclusion: In this small-sized preliminary study, the WBV at both shear rates revealed no difference between the CD and controlgroups. There was also no impact of CD treatment on WBV at follow-up. However, further large-scale studies are necessary toconfirm our study findings.

🔖

Cite This Article

Demir, Ö., Canpolat, A. G., Öksüz, S. B. T. (2022). Whole Blood Viscosity as a Marker of Thrombosis in Cushing’s Disease: An Actor or Ineffective Factor. European Journal of Therapeutics, Cilt: 27 - Sayı: 1, 73–77. https://ajindex.com/articles/512139

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 2002
  2. [Crossref] 2. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, et al. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 2010
  3. [Crossref] 3. Güneş H, Kirişci M. The Relationship Between Whole Blood Viscosity and Deep Vein Thrombosis. Turkiye Klinikleri J Cardiovasc Sci 2018
  4. [Crossref] 4. Toraldo DM, Peverini F, De Benedetto M, De Nuccio F. Obstructive sleep apnea syndrome: blood viscosity, blood coagulation abnormalities, and early atherosclerosis. Lung 2013
  5. [Crossref] 5. Weidman J, Sloop G, St Cyr JA. Validated formulae for estimation of whole blood viscosity underestimate the influence of erythrocyte aggregation and deformability. Ther Adv Cardiovasc Dis 2016
  6. [Crossref] 6. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015
  7. [Crossref] 7. Szakacs Z, Csiszar B, Kenyeres P, Sarlós P, Erőss B, Hussain A, et al. Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol. BMJ open 2019
  8. e026315. [Crossref] 8. Suarez MG, Stack M, Hinojosa-Amaya JM, Mitchell MD, Varlamov EV, Yedinak CG, et al. Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study. J Endocr Soc 2020
  9. bvz033. [Crossref] 9. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, et al. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul Fibrinolysis 1999
  10. [Crossref] 10. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MTB, Fliers E, et al. Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 2009
  11. [Crossref] 11. Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, et al. Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand fa